Phase 2 Commencing for Colorectal Drug

Share this content:

(ChemotherapyAdvisor) – Phase 2 clinical trials are about to begin for MORAb-004, a candidate therapy for metastatic colorectal cancer, according to an announcement today from Morphotek, Inc., Exton, PA. MORAb-004, a monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1), will enter a randomized, double-blind, placebo-controlled, multicenter study to evaluate its safety and efficacy in the treatment of metastatic colorectal cancer that is refractory to all standard therapy. 

The primary objective of the trial is to determine progression-free survival in patients with chemorefractory metastatic colorectal cancer. Secondary objectives include assessment of an overall survival benefit, identification of biomarkers to predict efficacy, and safety of single agent MORAb-004, according to the company.

The trial, which will be conducted at clinical sites in the United States, is expected to enroll up to 160 patients. The goal of these investigations is to identify those patients who had a clinically meaningful response to MORAb-004.

"We are excited to have initiated this Phase 2 study of MORAb-004 in metastatic colorectal cancer," stated Christina Coughlin, MD, PhD, Senior Director of Clinical Development at Morphotek. "New agents are needed for the treatment of metastatic colorectal cancer. The treatment of chemorefractory colorectal cancer remains an area of significant unmet medical need in the field of oncology. We are pleased to have the opportunity to collaborate with several key experts in this disease setting."

Press Release

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs